BRIEF-FDA Accepts Arcutis’ Supplemental New Drug Application For Zoryve

Reuters
24 Sep 2024

Sept 24 (Reuters) - Arcutis Biotherapeutics Inc

:

* FDA ACCEPTS ARCUTIS’ SUPPLEMENTAL NEW DRUG APPLICATION FOR ZORYVE® (ROFLUMILAST) FOAM FOR THE TREATMENT OF SCALP AND BODY PSORIASIS IN ADULTS AND ADOLESCENTS AGES 12 AND OVER

* ARCUTIS BIOTHERAPEUTICS INC - FDA SETS PDUFA TARGET ACTION DATE OF MAY 22, 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10